Source disclosure: February 12, 2026
GNI Group Ltd. [2160.T]
TOKYO, Feb 12 (Pulse News Wire) – GNI Group Ltd.
Regarding the acquisition of Gyre Pharmaceuticals shares, GNI aims to complete the purchase by December 31, 2026, but funding allocation priorities could shift based on higher growth opportunities. On F351, GNI clarified that while the conditionally approved drug's progress was detailed in previous filings, ongoing regulatory interactions and unresolved requirements remain key factors affecting the New Drug Application timeline.
GNI also noted that despite recent geopolitical tensions, maintaining operations in China aligns with long-term strategic interests due to the region's growing importance in pharmaceutical innovation. Separately, GNI commented on its collaboration with Astellas Pharma, stating that details of milestones and progress would not be disclosed due to confidentiality agreements.
Additionally, GNI explained that the abandonment of a non-solicitation clause allowed for more flexible strategic options without disrupting the merger framework.
AI-translated content. 🟡 Confidence: Standard See terms • Original filing